Salvage regimens in PCNSL based on prospective trials
| Study . | Agents . | Patients, n . | ORR* (%) . | Median PFS, mo . | Median OS, mo . |
|---|---|---|---|---|---|
| Fischer et al, 200660 | Topotecan | 27 | 9/27 (33) | 2 | 8.4 |
| Reni et al, 200761 | Temozolomide | 36 | 11/36 (31) | 2.8 | 3.9 |
| Soussain et al, 200852 | CYVE+ASCT | 43 | 20/40 (50) | 11.6 | 18.3 |
| Batchelor et al, 201162 | Rituximab | 12 | 5/12 (42) | 1.9 (57 d) | 20.9 |
| Raizer et al, 201263 | Pemetrexed | 11 | 6/11 (55) | 5.7 | 10.1 |
| Rubenstein et al, 201336 | IT rituximab+IT MTX | 14 | 6/14 (43) | 1.2 | NR |
| Nayak et al, 201364 | Rituximab+TMZ+pred | 16 | 5/14 (36) | 1.6 (7 wk) | NR |
| Korfel et al, 201655 | Temsirolimus | 37 | 20/37 (54) | 2.1 | 3.7 |
| Grommes et al, 201711 | Ibrutinib | 13 | 10/13 (77) | 4.6 | 15 |
| Grommes et al, 201945 | Ibrutinib/MTX/rituximab | 15 | 8/15 (80) | 9.2 | NR |
| Soussain et al, 201956 | Ibrutinib | 52 | 27/52 (52) | 4.8 | 19.2 |
| Ghesquieres et al, 201944 | Lenalidomide/rituximab | 45 | 28/45 (62) | 7.8 | 17.7 |
| Tun et al, 201858 | Pomalidomide | 25 | 12/25 (48) | 5.3 | NR |
| Rubenstein et al, 201859,60 | Lenalidomide | 13 | 8/13 (62) | NR | NR |
| Study . | Agents . | Patients, n . | ORR* (%) . | Median PFS, mo . | Median OS, mo . |
|---|---|---|---|---|---|
| Fischer et al, 200660 | Topotecan | 27 | 9/27 (33) | 2 | 8.4 |
| Reni et al, 200761 | Temozolomide | 36 | 11/36 (31) | 2.8 | 3.9 |
| Soussain et al, 200852 | CYVE+ASCT | 43 | 20/40 (50) | 11.6 | 18.3 |
| Batchelor et al, 201162 | Rituximab | 12 | 5/12 (42) | 1.9 (57 d) | 20.9 |
| Raizer et al, 201263 | Pemetrexed | 11 | 6/11 (55) | 5.7 | 10.1 |
| Rubenstein et al, 201336 | IT rituximab+IT MTX | 14 | 6/14 (43) | 1.2 | NR |
| Nayak et al, 201364 | Rituximab+TMZ+pred | 16 | 5/14 (36) | 1.6 (7 wk) | NR |
| Korfel et al, 201655 | Temsirolimus | 37 | 20/37 (54) | 2.1 | 3.7 |
| Grommes et al, 201711 | Ibrutinib | 13 | 10/13 (77) | 4.6 | 15 |
| Grommes et al, 201945 | Ibrutinib/MTX/rituximab | 15 | 8/15 (80) | 9.2 | NR |
| Soussain et al, 201956 | Ibrutinib | 52 | 27/52 (52) | 4.8 | 19.2 |
| Ghesquieres et al, 201944 | Lenalidomide/rituximab | 45 | 28/45 (62) | 7.8 | 17.7 |
| Tun et al, 201858 | Pomalidomide | 25 | 12/25 (48) | 5.3 | NR |
| Rubenstein et al, 201859,60 | Lenalidomide | 13 | 8/13 (62) | NR | NR |
CYVE, cytarabine + etoposide; NR, not reached; pred, methylprednisone; TMZ, temozolomide.
Partial response/complete response.